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Abstract
Effects of prolonged metabolic (glucose deprivation) and hormonal [insulin-like growth factor I (IGF-I)] challenge on regulation of
glucose transporter (GLUT) expression, glucose transport rate and possible signaling pathways involved were studied in the neuroendocrine
chromaffin cell. The results show that bovine chromaffin cells express both GLUT1 and GLUT3. Glucose deprivation and IGF-I activation
led to an elevation of GLUT1 and GLUT3 mRNA, the strongest effect being that of IGF-I on GLUT3 mRNA. Both types of stimulus
increased the GLUT1 protein content in a cycloheximide (CHX)-sensitive manner, and the glucose transport rate was elevated by 3- to 4-fold
after 48 h under both experimental conditions. IGF-I-induced glucose uptake was totally suppressed by CHX. In contrast, only f50% of
transport activation in glucose-deprived cells was sensitive to the protein synthesis inhibitor. Specific inhibitors of mTOR/FRAP and p38
MAPK each partially blocked IGF-I-stimulated glucose transport, but had no effect on transport rate in glucose-deprived cells. The results are
consistent with IGF-I-activated transport being completely dependent on new GLUT protein synthesis while the enhanced transport in
glucose-deprived cells was partially achieved independent of new synthesis of proteins, suggesting a mechanism relying on preexisting
transporters.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The adrenal medulla plays an important function in
glucose homeostasis in vivo, and hypoglycemic conditions
cause a preferential release of adrenaline from the gland.
The response is elicited via the central nervous system
leading to activation of sympathetic cholinergic neurons
directly innervating the adrenomedullary chromaffin cells.
Extreme hypoglycemic conditions also induce a non-neuro-
genic adrenaline release in rats [1], indicating a direct effect
of low glucose on cellular functions in chromaffin cells.
These excitable neuroendocrine cells have themselves a
great demand for energy due to high synthetic activity.
Furthermore, a significant amount of ATP is utilized by
the Na+/K+-ATPase to energize repolarisation of the plasma
membrane following activation of the cells. Glucose is the
main energy source for neuronal cells and appears also to be
the preferred energy substrate in chromaffin cells [2], and
nicotinic activation has been shown to enhance glucose
uptake in these cells [3].
Glucose transport across the cell membrane is the rate-
limiting step in glucose metabolism and energy production
in most cell types. A family of glucose transporter (GLUT)
proteins mediates glucose uptake, which occurs by facili-
tated diffusion in most cells and tissues. To date, nine
glucose transporter genes have been identified [4–6],
encoding for the protein isoforms GLUT1–GLUT9. The
GLUT proteins exhibit sequence similarities, but differ in
regulation and tissue distribution [7,8]. GLUT1, ubiqui-
tously expressed in mammalian tissues, is assumed to
account for basal cellular glucose uptake [9]. GLUT4,
the insulin-sensitive transporter, is expressed in tissues
such as fat, skeletal and cardiac muscle. GLUT3 expres-
sion is highest in the brain and neuronal tissues in
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mammals [10,11], with lower amounts present in periph-
eral tissues such as placenta, liver, heart and kidney in
humans [12].
Regulation of glucose transport in response to environ-
mental signals is complex and varies according to cell type
and to the external stimuli. In general, glucose transport may
be augmented by anabolic and metabolic stimuli [13]. Glu-
cose deprivation and hypoxia represent typical metabolic
stimuli, while insulin is the classical anabolic hormone that
stimulates glucose transport independent of an increased
demand for glucose. Acute stimulation of glucose transport
involves translocation of GLUTs located intracellularly to the
plasma membrane and/or changes in the activity of surface
transporters. Prolonged activation of glucose transport is
normally ascribed to an increase in the total pool of GLUT
proteins in the cells, as a result of activation at the transcrip-
tional, translational and/or posttranslational level [14–18].
Furthermore, it has become apparent that when a cell
expresses more than one GLUT isoform, these isoforms
may be regulated differently, as demonstrated in 3T3-L1
adipocytes and L6 muscle cells in which prolonged insulin
stimulation increased GLUT1 but reduced GLUT4 protein
[19,20].
The signaling pathways underlying these responses are
less well understood. According to Taha et al. [21–23], the
ERK1/ERK2 cascade, p38 MAPK and mTOR/FRAP and its
downstream targets may be implicated in the induction of
GLUT1 as well as GLUT3. It has also been established that
more than one of these signaling pathways may be activated
in parallel in various cell types to achieve rapid and
sustained increments in glucose transport. In a previous
report, we demonstrated that insulin-like growth factor I
(IGF-I) acutely up-regulated glucose transport in chromaffin
cells in a PI3-kinase-dependent manner while p38 MAPK
activation in part accounted for an enhanced glucose uptake
in response to cellular stress like exposure to arsenite and
anisomycin [24]. The aim of the present study was to
elucidate the effect of prolonged metabolic stress on glucose
transport in chromaffin cells and possible implications for
glucose transporter expression. Long-term effects of the
anabolic stimuli IGF-I were also studied to illuminate
possible differences between the two types of stimulus with
respect to regulation of transport rate and possible signaling
pathways involved.
2. Materials and methods
2.1. Materials
Collagenase type I, DNAse type 1, 2-deoxy-D-glucose,
cytochalasin B, cycloheximide (CHX), rapamycin, PD98059
and SB203580 were obtained from Sigma, St. Louis, MO.
Dulbecco’s modified Eagle’s medium (DMEM), Ham’s
nutrient F12 medium (F12), glucose-free DMEM, newborn
calf serum (NBCS), and antibiotics were from Gibco BRL,
Paisly, Scotland. Urografin-60 was obtained from Schering
AG, Berlin, Germany. 2-[3H]-deoxyglucose (specific activ-
ity 30.6 Ci/mmol) and [32P]-dCTP (specific activity 3000 Ci/
mmol) were purchased from Amersham Life Sciences,
Buckinghamshire, UK. Recombinant human IGF-I was from
Peninsula Laboratories, Meyerside, UK. Polyclonal anti-
bodies to the rat GLUT1 was obtained from East Acre
Biologicals, Southbridge, MA. Horseradish peroxidase-con-
jugated secondary antibody, LumiGLO chemiluminescent
detection reagent, and high molecular weight protein stand-
ard were obtained from New England Biolabs, Beverly, MA.
Reagents for electrophoresis were from Bio-Rad Laborato-
ries, Hercules, CA, and Hybond ECL nitrocellulose mem-
brane, Hybond-N nylon membrane and Hyperfilmk MP
were obtained from Amersham Life Sciences. Plastic ware
for cell culture was purchased from NUNC, Roskilde, Den-
mark.
2.2. Isolation and culture of chromaffin cells
Chromaffin cells were isolated from bovine adrenal
medullae as previously described in detail [25]. The cells
were seeded at a final density of 4.5 105 cells/cm2 in
DMEM/F12 (1:1) supplemented with 10% NBCS, 100 U/ml
penicillin-G, 50 U/ml Nystatin, 40 Ag/ml garamycin and 20
AM 5-fluorodeoxyuridine and 10 AM cytosine arabinose to
prevent proliferation of contaminating cells. Cells were kept
at 37 jC in an atmosphere of 5% CO2 in air. The experi-
ments were carried out on days 4–5. Cells exposed to IGF-I
were preincubated for at least 4 h in serum-free medium
before stimulation. When the effect of glucose deprivation
was studied, cells were adapted to a glucose-free DMEM
without the F12 component, but supplemented with 3.15 g
glucose/l (17 mM, standard DMEM/F12 concentration), 5%
NBCS and antibiotics as described above for 24 h before
starvation challenge.
2.3. Glucose transport assay
Transport measured as uptake of 0.5 mM 2-deoxyglucose
and 0.5 ACi 2-3H-labelled deoxyglucose/ml, at room tem-
perature was terminated after 3 min by adding ice-cold
Krebs–Ringer phosphate buffer (10 mM Na phosphate
buffer, 129 mM NaCl, 5.1 mM KCl, 1.3 mM MgSO4, 1
mM CaCl2, pH 7.4) containing 20 AM cytochalasin B [24].
The medium was removed; cells were washed three times
with ice-cold PBS and solubilised in 0.2 M NaOH. Aliquots
were taken for scintillation counting and protein was deter-
mined by the Bio-Rad micro assay system with bovine
serum albumin as standard.
2.4. Primer design and establishment of bovine GLUT1 and
GLUT3 probes
Primer design was based on comparison of published
sequences of ovine GLUT3 [26] (genEMBL accession
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number L39214) and bovine GLUT1 [27] (genEMBL acces-
sion number M60448) transporters. GLUT3 forward (21
mer: 5V-ACTCAATGCTTATTGTCAACC-3V) and reverse
(22 mer: 5V-AGATCTCTCCAATGTACATAGG-3V) primers
correspond to nucleotides 390–410 and 530–551, respec-
tively, of ovine GLUT3 cDNA, and GLUT1 forward (21
mer: 5V-GATGAGATTGCTTCTGGCTTC-3V) and reverse
(23 mer: 5V-GTGGGTGAAGGAGACTCTGGCTG-3V) pri-
mers to nucleotides 1551–1571 and 1912–1934, respec-
tively, of bovine GLUT1 cDNA.
Total RNA was extracted from cultured chromaffin cells
using TRIZOL Reagent (Gibco BRL) according to the
instruction of the manufacturer. mRNAwas isolated, reverse
transcribed to cDNA, and subjected to PCR using the
specific primers for GLUT1 and GLUT3 genes. PCR ampli-
fications were carried out on a Mastercycler gradient (Eppen-
dorf, Germany) with the following thermocycle profile: 95
jC 10 min denaturation; 25 cycles of 94 jC 30 s, 65
jC 30 s, 72 jC 1 min; followed by 10 min extension at
72 jC. Amplified PCR products were ligated into pCRII-
TOPO vector (Invitrogen, The Netherlands) and sequenced
using ABI PRISMk BigDyek Terminator Cycle Sequenc-
ing Ready Reaction Kit in an Applied Biosystem 377 DNA
sequencer (Foster City, CA).
2.5. Northern blot analysis
Total cellular RNAwas prepared from cells grown on 23
cm2 dishes by TRIZOL Reagent. RNA pellets were dis-
solved in formamide, and quantified by absorbance meas-
urements at 260 nm. RNA (25 Ag) was denatured and size
separated by gel electrophoresis through 1% agarose/1.2%
formaldehyde gel. The integrity and loading of RNA were
confirmed by UV visualization of ethidium bromide-stained
ribosomal RNA. RNAwas blotted on to a Hybond-N nylon
membrane by TurboBlotter Rapid Downward Transfer Sys-
tem (Schleicher & Schuell, Germany) and baked at 80 jC
for 2 h. The membranes were prehybridized in buffer
containing 0.5 M NaPi, 7% SDS, 1 mM EDTA and 100
Ag/ml denaturated herring sperm DNA at 65 jC for at least
1 h. Bovine GLUT1 and GLUT3 cDNA probes were
labeled with 32P-dCTP using T7QuickPrime Kit (Pharmacia
Biotech, Sweden), and purified by QIAquick Nucleotide
Removal Kit (Qiagen, Crawley, UK). The probes were
hybridized sequentially to the membranes overnight at 65
jC. The membranes were then washed three times at room
temperature in 2 SSC/0.1% SDS, once in 2 SSC/0.1%
SDS for 5 min at 50 jC and twice in 0.15 SSPE/0.1%
SDS for 15 min at 50 jC. Membranes were exposed to
Fig. 1. Time courses of glucose transport and GLUT1 and GLUT3 expression in response to glucose deprivation and IGF-I stimulation. Chromaffin cells were
grown in the presence of the given concentrations of glucose (A) or stimulated with 10 8 M IGF-I (B) for the indicated time periods, and 2-deoxyglucose
uptake was determined as described under Materials and methods. Values, expressed as fold increase above control levelF S.E., are the means of six
independent experiments. Total RNAwas extracted from cells grown in medium containing low glucose (0.02 g glucose/l) (C) and from cells stimulated with
10 8 M IGF-I (D). Samples of 25 Ag total RNA were subjected to Northern blot analysis using GLUT1 and GLUT3 probes. Ethidium bromide-stained 28S
rRNA is presented as loading control. The results of representative experiments are given.
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Kodak X-AR autoradiograph film at  80 jC for 4–5 days.
Reprobing of the membranes was performed after stripping
in 0.1% SDS solution.
2.6. Western immunoblot analysis
Total cell membranes was prepared essentially as pre-
viously described [25]. Cells, obtained from 9.6 cm2 plates,
were suspended in buffer [25 mM HEPES (pH 7.4), 1 mM
EDTA (pH 8.0), containing 1 Ag/ml pepstatin, 1 Ag/ml
leupeptin, 1 Ag/ml aprotinin, 1 Ag/ml phenylmetylsulfonyl
fluoride] and homogenized by the use of a polytron. The
homogenate was centrifuged at 750 g for 10 min to
remove nuclei, and the membranes were collected from
the resulting supernatant by centrifugation at 200,000 g
for 10 min at 4 jC. Membrane pellets were dissolved in
sample buffer [2.3 M Urea, 1.5% SDS, 15 mM Tris (pH
7.4), 100 mM dithiothreitol], and protein was determined by
detergent-compatible protein assay kit (Perbio Science Ltd.,
Cheshire, UK). Equal membrane samples of 35 Ag protein
were separated on 10% SDS-PAGE gels, and blotted to
nitrocellulose membranes in a horizontal semidry system
(Pharmacia). The nitrocellulose membranes were incubated
for 1 h at room temperature with polyclonal antibodies
against rat GLUT1 in a 1:5000 dilution. Immunoreactive
bands were detected by LumiGLO chemiluminescent
reagent and exposure to Hyperfilm and quantified by
densitometry scanning.
2.7. Statistics
Statistical evaluation of data was performed by one-way
analysis of variance followed by Tukey test for multiple
comparisons.
3. Results
3.1. Long-term effects of glucose deprivation and IGF-I on
glucose transport and transporter mRNA expression
We have previously estimated a basal uptake rate of
f1.1 nmol deoxyglucose/mg protein/min in chromaffin
cells [24]. Basal transport rate in the present experiments
was 0.9F 0.4 nmol deoxyglucose/mg protein/min and thus
in agreement with our previous data. The effect of glucose
deprivation on transport activity was studied by incubating
the cells in glucose- and serum-free medium supplemented
with 0.02, 0.2, or 1.0 g glucose/l for 1–48 h. The results,
expressed relative to control cells kept in medium contain-
ing 3.15 g glucose/l (17 mM, standard glucose concentra-
tion in DMEM/F12), demonstrated a time- and dose-
dependent increase in transport activation (Fig. 1A). Cells
incubated in medium containing 1.0 g glucose/l showed no
change in glucose transport over time, whereas an enhanced
transport (f1.5-fold increase) was seen already after 1 h in
cells kept in 0.2 or 0.02 g glucose/l. The uptake rate
continued to rise and was f4-fold higher than in controls
at 48 h for cells kept at 0.2 g glucose/l. Due to cell
detachment on prolonged culture in medium containing
0.02 g glucose/l, transport beyond 24 h was not measured.
The effect of prolonged IGF-I (10 8 M) stimulation,
expressed relative to basal transport at each time point, is
illustrated in Fig. 1B. The transport rate, which was doubled
by acute IGF-I stimulation, developed slowly beyond 24 h
Fig. 2. Effect of glucose deprivation and IGF-I stimulation on GLUT1
protein expression. Cells were exposed to low glucose (0.2 g glucose/l)
(hatched bars) or 10 8 M IGF-I (open bars) for the time indicated. Total
cell membranes were isolated as described in Materials and methods and
aliquots of 35 Ag protein were analyzed by SDS-PAGE and Western blot
using polyclonal antibody raised against GLUT1. Representative immuno-
blots are shown (A), and the mean resultsF S.E. of three independent
experiments, quantified by densitometry, are given in (B). *Significantly
different from control (0), P < 0.05.
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to reach a valuef3-fold higher than basal transport at 48 h.
IGF-I added for the last 30 min to cells glucose starved for
24 h had no additional stimulatory effect on transport rate
(results not shown).
The effect of the two types of stimulus was also studied
at the level of GLUT mRNA expression. For this purpose,
specific probes corresponding to the bovine GLUT1 and
GLUT3 were made. The bovine GLUT3 has not been
cloned and we therefore constructed a probe on the basis
of the published sequence of ovine GLUT3 [26]. A 161-bp
RT-PCR product was purified and sequence analysis revealed
a cDNA exhibiting 99% identity to position 390–551 bp of
the full-length ovine GLUT3 cDNA sequence. A 384-bp RT-
PCR product, with 100% identity to the 1551- to 1935-bp
region of the full-length bovine GLUT1 cDNA was used as
probe for the detection of GLUT1 mRNA. Glucose depri-
vation caused a relatively modest increase in both GLUT1
and GLUT3 mRNA; however, it was clearly visible after 6 h
(Fig. 1C). IGF-I induced a similar modest increase in
GLUT1 mRNA, with no great change beyond 6 h. This
was in sharp contrast to the level of GLUT3 mRNA, which
continued to rise steeply in the presence of IGF-I over the
48-h period and with a distinct effect observed already after
1 h (Fig. 1D).
3.2. GLUT1 protein expression and the effect of CHX
We have previously established that rat GLUT1 antibody
detects the bovine GLUT1 protein in chromaffin cells [25],
and the rat antibody was therefore applied to study the
effects of glucose deprivation and IGF-I on GLUT1 protein
expression by Western immunoblots. When equal amounts
of membrane protein were subjected to gel electrophoresis,
an increase in GLUT1 protein relative to total membrane
protein was observed in response to both treatments (Fig.
2A) and densitometry scanning indicated that the GLUT1
protein expression was nearly 2-fold under both conditions
(Fig. 2B). An additional anti-GLUT1 immunoreactive pro-
tein with a molecular weight of 37,000 appeared in extracts
of cells kept in low glucose medium for 24 and 48 h. This
protein most likely corresponds to a nonglycosylated form
of GLUT1 [17,28,29], but because its transport activity is
questionable [30,31], it was not studied in further detail.
Fig. 3. Effect of cycloheximide on glucose transport activity and GLUT1
expression. Cells were incubated in medium containing normal (3.15 g/l) or
low (0.2 g/l) amounts of glucose (A) or with or without 10 8 M IGF-I (B)
in the absence or presence of CHX (2 mg/ml) for the time indicated. Uptake
of 2-deoxyglucose was measured, and values, expressed as fold increase
above control level for each time point, are the meansF S.E. of six
independent experiments. Total cell membranes were obtained from cells
grown in low glucose (0.2 g/l) medium (C) or in the presence of 10 8 M
IGF-I (D) for 48 h, and aliquots of 35 Ag protein were analyzed by SDS-
PAGE and Western blot. A representative immunoblot out of three
independent experiments is given. *Significantly different from basal
( P< 0.02), and #significantly different from respective stimuli in the
absence of inhibitor ( P< 0.02).
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Due to lack of a commercial antibody cross-reacting with
the bovine GLUT3 protein [25], we were unable, however,
to study changes in the level of GLUT3 protein.
To assess if ongoing protein synthesis was required for
the observed changes in glucose transport and GLUT1
content in response to the two different treatments, cells
were incubated in the presence of the protein synthesis
inhibitor CHX (2 Ag/ml) throughout the experimental
period. CHX affected neither the content of GLUT1 protein
(results not shown) nor the enhanced transport rate under the
two conditions at 5 h (Fig. 3A and C). However, at 48 h,
very distinct differences in the CHX effect were observed.
In contrast to the IGF-I-induced glucose transport, which
was completely attenuated by CHX (Fig. 3C), the enhanced
transport rate in glucose-deprived cells was reduced by only
f50% (Fig. 3A). The increment in GLUT1 protein and also
the 37-kDa form in glucose-starved cells was on the other
hand fully suppressed by CHX (Fig. 3B), as was also the
case for IGF-I-induced GLUT1 expression (Fig. 3D).
Hence, IGF-I-stimulated transport relied completely on
GLUT synthesis while the enhanced transport rate in glu-
cose-deprived cells was accomplished by two mechanisms;
one dependent on synthesis of new transporters and one
mechanism independent of new transporters.
3.3. Cellular signaling pathways involved in transport
activation
We have previously demonstrated that enhanced glucose
transport in response to cellular stressors like arsenite and
anisomycin in part depends on the stress-activated p38
MAPK, while the acute effect of IGF-I is channeled through
PI3-kinase [24]. Presently, initial experiments showed that
the PI3-kinase inhibitor wortmannin (100 nM) had no effect
on glucose transport in glucose-deprived cells, while a 20%
reduction in uptake was observed in cells stimulated by
IGF-I (results not shown). This relatively modest effect of
wortmannin might relate to its instability in aqueous sol-
utions [32]. We therefore decided to use rapamycin, an
inhibitor of the downstream target, mTOR/FRAP, to eluci-
date a potential role of PI3-kinase-linked pathways. Fur-
thermore, cells were subjected to the two types of stimulus
in the presence of the MEK1 inhibitor PD98059 or the p38
MAPK inhibitor SB203580. The results presented in Table
1 show that neither of the inhibitors affected transport
activity in glucose-deprived cells, nor did PD98059 influ-
ence IGF-I-activated transport. Rapamycin and SB203580
each reduced IGF-I-stimulated uptake by approximately
30%, but when combined, the two inhibitors had no additive
effect. Thus, mTOR and p38 MAPK each appeared to only
partially mediate the response to IGF-I.
4. Discussion
In the present report, we have compared long-term
effects of metabolic and anabolic stimuli on glucose trans-
port in bovine chromaffin cells, and the implication of
changes at the level of transporter expression. GLUT3,
originally cloned from a human fetal skeletal muscle cell
line, is expressed mainly in brain tissue of all species studied
[10,11]. Although GLUT3 has been identified in the rat
adrenomedullary PC12 tumor cell line [33,34], the present
study is the first to establish the presence of GLUT3 mRNA
transcripts in normal chromaffin cells. In brain, GLUT1
expression is limited to the blood-brain barrier while
GLUT3 is restricted to neurons. The rat L6 skeletal muscle
cell line on the other hand expresses GLUT1 and GLUT3 in
addition to GLUT4 [35]. We have previously identified
GLUT1 in freshly isolated bovine chromaffin cells, suggest-
ing that the ubiquitously expressed GLUT1 isoform is a
natural constituent of the neuroendocrine chromaffin cell
[25]. In a recent report [3], we demonstrated that approx-
imately 50% of basal transport activity prevailed in chro-
maffin cells treated with genistein, acting as competitive
inhibitor of GLUT1 transport activity [36]. This observation
indicated the presence of an additional GLUT isoform, most
likely GLUT3 based on the presence of its mRNA in the
cells as presently shown.
Consistent with numerous in vitro and in vivo studies
reporting on enhanced glucose transport in response to
prolonged glucose deprivation and IGF-I activation, both
types of stimuli augmented transport rate in chromaffin
cells. However, as opposed to IGF-I-activated transport,
which was totally suppressed by CHX, the increment in
transport activity in glucose-starved chromaffin cells was
Table 1
Effect of PD98059, SB203580 and rapamycin on glucose transport activated by prolonged glucose deprivation and IGF-I stimulation
No inhibitor PD98059 SB203580 Rapamycin SB203580/Rapamycin
3.15 g/l glucose 1.0 (3) 1.2F 0.1 (3) 0.8F 0.01 (3) 1.0F 0.03 (3)
0.02 g/l glucose 2.7F 0.2 (3) 2.6F 0.04 (3) 2.5F 0.3 (3) 2.4F 0.1 (3)
Basal 1.0 (6) 1.1F 0.1 (5) 0.7F 0.1 (6) 0.8F 0.1 (6) 0.5F 0.02 (2)
10 8 M IGF-I 2.6F 0.3 (6) 2.2F 0.1 (5) 1.6F 0.1* (6) 1.5F 0.1* (6) 1.3F 0.2 (2)
Chromaffin cells were incubated for 24 h in medium containing normal (3.15 g/l) or low (0.02 g/l) amounts of glucose or with or without 10 8 M IGF-I in the
absence (no inhibitor) or presence of 50 AM PD98059, 20 AM SB203580 or 30 ng/ml rapamycin. Glucose uptake was measured as described in Materials and
methods, and expressed as fold increase above basal rateF S.E. The number of individual experiments is given in parentheses.
*Significantly different from the IGF-I response in the absence of inhibitor ( PV 0.05).
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diminished by only 50% in spite of a complete suppression
of new synthesis of GLUT1 by the protein synthesis
inhibitor. Hence, a substantial fraction of transport activity
in chromaffin cells in response to energy depletion relied on
a CHX-insensitive mechanism. Activation of preexisting
transporters involving a p38 MAPK-dependent mechanism
has been suggested necessary to obtain full activity of the
GLUT4 transporter [22]. It seems, however, unlikely that a
similar p38 MAPK-dependent activation of GLUT1 and
possibly GLUT3 accounted for the CHX-insensitive trans-
port in the glucose-deprived chromaffin cells as the p38
MAPK inhibitor SB203580 had no effect. In a recent report,
von der Crone et al. [37] have suggested that glucose
deprivation in 3T3-L1 adipocytes leads to induction of
GLUT1 transporters which is sorted to the plasma mem-
brane in an insulin-independent manner, and that a reduced
internalization rate of this GLUT1 pool may account for the
observed parallel increment in transport activity. A similar
change in internalization rate of GLUT1 and possibly
GLUT3 transporters may explain the enhanced transport
rate presently observed in glucose-deprived chromaffin
cells, although such a mechanism will necessarily apply
only to preexisting GLUT1 and possibly GLUT3 trans-
porters in cells kept in the presence of CHX. According to
Khayat et al. [35], a marked stabilization of GLUT3
accounted totally for enhanced glucose transport in a
CHX-insensitive manner in the L6 myotubes treated with
the mitochondrial uncoupler dinitrophenol. Although glu-
cose deprivation and mitochondrial uncoupling represent
two different forms for energy stress and therefore cannot be
directly compared, it is nevertheless tempting to hypothesize
that a similar stabilization of GLUT3 protein may explain
the ability of glucose-starved chromaffin cells to up-regulate
glucose transport even in continuous presence of CHX. The
CHX-sensitive transport was on the other hand paralleled by
suppression of new synthesis of GLUT1 protein. In view of
an increase, however moderate, in both GLUT1 and GLUT3
mRNA in response to glucose deficiency, it seems reason-
able to conclude that newly synthesized GLUT3 proteins
also in part accounted for the CHX-sensitive transport
activity.
GLUT1 belongs to a set of genes, encompassing vascular
endothelial growth factor (VEGF), erythropoietin and gly-
colytic enzymes, which are up-regulated under hypoxic
conditions as a compensatory mechanism to facilitate the
delivery of glucose to meet the demand for enhanced
glycolysis in the tissues [38]. Stabilization of subunit HIF-
1a of the hypoxia-inducible transcription factor HIF-1
appears vital for increased transcription of these down-
stream genes. It has been reported, however, that up-
regulation of the GLUT1 gene occurs mainly at a posttran-
scriptional level in a number of pathological conditions such
as hypoxia and glucose deprivation [39]. Thus, both hypo-
xia and hypoglycemia have been shown to increase the half-
life of intrinsically unstable GLUT1 and VEGF mRNA in
the C6 cell line [40], and in the case of GLUT1 mRNA,
stabilization involves a trans-acting factor (TAF) binding to
cis-acting elements in the 3V-untranslated region of GLUT1
mRNA [39]. Upstream signaling pathways involved in
transcriptional and posttranscriptional up-regulation of
GLUT1 are not known in detail. Full transcriptional activa-
tion and stabilization of the HIF-1 complex relies to a great
extent on posttranslational modifications of HIF-1a and
phosphorylation of HIF-1a by the MEK-1/p42/p44 MAPK
pathway enhances transcription activity, whereas the PI3-
kinase/PTEN/Akt/FRAP pathway is involved in HIF-1a
stabilization (see review in Ref. [38]). We were, however,
unable to demonstrate any effect of either the MEK-1
inhibitor PD98059 or rapamycin on transport activity in
glucose-deprived chromaffin cells, which suggested that
regulation of GLUT1 occurred mainly at a posttranscrip-
tional level in these cells.
The concomitant increase in GLUT1 mRNA and protein
and in transport rate in IGF-I-activated chromaffin cells,
totally abrogated by CHX, was consistent with changes in
transport rate being totally dependent on synthesis of new
transporter molecules. The effect of IGF-I appeared to be
partly channeled through p38 MAPK and mTOR/FRAP
signaling. As rapamycin and SB203580 inhibited transport
to the same extent without being additive, it seemed
possible that long-term IGF-I treatment activated p38
MAPK-dependent and PI3K/mTOR/FRAP-dependent sig-
naling pathways in parallel, the two separate pathways
converging at a more distal but common step. The most
striking feature of IGF-I activation was, however, the
pronounced stimulatory effect of IGF-I on GLUT3 mRNA
compared to GLUT1 mRNA, an effect of IGF-I which has
to our knowledge not been reported in the case of neuro-
endocrine cells. This clearly indicated a differential regu-
lation by IGF-I of the two gene products either at the
transcriptional level or by transcript stabilization. On the
basis of earlier reports on stimulatory effects of IGF-I on
GLUT3 protein synthesis [41], it seems reasonable to
assume an elevation in GLUT3 protein in the present
experiments and a consequent enhanced GLUT3-mediated
transport in addition to GLUT1-mediated transport. Accord-
ing to Taha et al. [22], the elevation of GLUT3 protein as
opposed to GLUT1 protein in L6 muscle cells in response to
prolonged insulin treatment was insensitive to rapamycin
and SB203580. In a similar manner, the partial effect of the
two inhibitors on glucose transport presently observed may
relate to suppression of GLUT1 synthesis while GLUT3
remained unaffected.
In summary, we demonstrate for the first time that normal
chromaffin cells express GLUT3. In contrast to glucose
transport activation by IGF-I, a large fraction of the en-
hanced glucose uptake in response to glucose deprivation
proved to be independent of new synthesis of transporters. It
is hypothesized that reduced internalization rate of preexist-
ing transporters and stabilization of GLUT3 glucose trans-
porters may account for the glucose transport in glucose-
deprived cells.
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